These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
131 related articles for article (PubMed ID: 22402907)
1. Intact interferon signaling in peripheral blood leukocytes of high-grade osteosarcoma patients. Buddingh EP; Ruslan SE; Berghuis D; Gelderblom H; Anninga JK; Hogendoorn PC; Egeler RM; Schilham MW; Lankester AC Cancer Immunol Immunother; 2012 Jun; 61(6):941-7. PubMed ID: 22402907 [TBL] [Abstract][Full Text] [Related]
2. The role of interferons in the treatment of osteosarcoma. Whelan J; Patterson D; Perisoglou M; Bielack S; Marina N; Smeland S; Bernstein M Pediatr Blood Cancer; 2010 Mar; 54(3):350-4. PubMed ID: 19902521 [TBL] [Abstract][Full Text] [Related]
3. Anti-EGFR antibody cetuximab enhances the cytolytic activity of natural killer cells toward osteosarcoma. Pahl JH; Ruslan SE; Buddingh EP; Santos SJ; Szuhai K; Serra M; Gelderblom H; Hogendoorn PC; Egeler RM; Schilham MW; Lankester AC Clin Cancer Res; 2012 Jan; 18(2):432-41. PubMed ID: 22090361 [TBL] [Abstract][Full Text] [Related]
4. The Raf Kinase Inhibitor Sorafenib Inhibits JAK-STAT Signal Transduction in Human Immune Cells. Martin del Campo SE; Levine KM; Mundy-Bosse BL; Grignol VP; Fairchild ET; Campbell AR; Trikha P; Mace TA; Paul BK; Jaime-Ramirez AC; Markowitz J; Kondadasula SV; Guenterberg KD; McClory S; Karpa VI; Pan X; Olencki TE; Monk JP; Mortazavi A; Tridandapani S; Lesinski GB; Byrd JC; Caligiuri MA; Shah MH; Carson WE J Immunol; 2015 Sep; 195(5):1995-2005. PubMed ID: 26238487 [TBL] [Abstract][Full Text] [Related]
5. Interferon-alpha as the only adjuvant treatment in high-grade osteosarcoma: long term results of the Karolinska Hospital series. Müller CR; Smeland S; Bauer HC; Saeter G; Strander H Acta Oncol; 2005; 44(5):475-80. PubMed ID: 16118081 [TBL] [Abstract][Full Text] [Related]
6. Correlation of High-Grade Osteosarcoma Response to Chemotherapy with Enhanced Tissue Immunological Response: Analysis of CD95R, IFN-γ, Catalase, Hsp70, and VEGF. Mustokoweni S; Mahyudin F; Setiawati R; Nugrahenny D; Hidayat M; Kalim H; Mintaroem K; Fitri LE; Hogendoorn PCW Virchows Arch; 2024 Jun; 484(6):925-937. PubMed ID: 38748263 [TBL] [Abstract][Full Text] [Related]
7. Interferon-α/β receptor as a prognostic marker in osteosarcoma. Kubo T; Shimose S; Matsuo T; Fujimori J; Arihiro K; Ochi M J Bone Joint Surg Am; 2011 Mar; 93(6):519-26. PubMed ID: 21411701 [TBL] [Abstract][Full Text] [Related]
8. Luteolin sensitizes the antiproliferative effect of interferon α/β by activation of Janus kinase/signal transducer and activator of transcription pathway signaling through protein kinase A-mediated inhibition of protein tyrosine phosphatase SHP-2 in cancer cells. Tai Z; Lin Y; He Y; Huang J; Guo J; Yang L; Zhang G; Wang F Cell Signal; 2014 Mar; 26(3):619-28. PubMed ID: 24333668 [TBL] [Abstract][Full Text] [Related]
9. Multiparametric flow cytometric analysis of inter-patient variation in STAT1 phosphorylation following interferon Alfa immunotherapy. Lesinski GB; Kondadasula SV; Crespin T; Shen L; Kendra K; Walker M; Carson WE J Natl Cancer Inst; 2004 Sep; 96(17):1331-42. PubMed ID: 15339971 [TBL] [Abstract][Full Text] [Related]
11. Low expression of interferon-stimulated genes in active multiple sclerosis is linked to subnormal phosphorylation of STAT1. Feng X; Petraglia AL; Chen M; Byskosh PV; Boos MD; Reder AT J Neuroimmunol; 2002 Aug; 129(1-2):205-15. PubMed ID: 12161037 [TBL] [Abstract][Full Text] [Related]
12. [Amplification of γδ T cells in PBMCs of healthy donors and osteosarcoma patients stimulated by zoledronate]. Li ZX; Sun LL; Cheng RL; Sun ZW; Ye ZM Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2012 Aug; 28(8):822-4. PubMed ID: 22863589 [TBL] [Abstract][Full Text] [Related]
13. [Effect of zoledronate on the cytotoxicity of γδ T cells from PBMCs of osteosarcoma patients against osteosarcoma]. Li Z; Tang J; Sun L; Ye Z Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2013 Jan; 29(1):6-9. PubMed ID: 23294710 [TBL] [Abstract][Full Text] [Related]
14. Chemotherapy-resistant osteosarcoma is highly susceptible to IL-15-activated allogeneic and autologous NK cells. Buddingh EP; Schilham MW; Ruslan SE; Berghuis D; Szuhai K; Suurmond J; Taminiau AH; Gelderblom H; Egeler RM; Serra M; Hogendoorn PC; Lankester AC Cancer Immunol Immunother; 2011 Apr; 60(4):575-86. PubMed ID: 21240486 [TBL] [Abstract][Full Text] [Related]
15. Ex vivo allogeneic stimulation significantly improves expansion of cytokine-induced killer cells without increasing their alloreactivity across HLA barriers. Todorovic M; Mesiano G; Gammaitoni L; Leuci V; Giraudo Diego L; Cammarata C; Jordaney N; Carnevale-Schianca F; Gallo S; Fagioli F; Piacibello W; Elia AR; Pignochino Y; Dell'aglio C; Grignani G; Cignetti A; Aglietta M; Sangiolo D J Immunother; 2012 Sep; 35(7):579-86. PubMed ID: 22892454 [TBL] [Abstract][Full Text] [Related]
16. Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trial. Marina NM; Smeland S; Bielack SS; Bernstein M; Jovic G; Krailo MD; Hook JM; Arndt C; van den Berg H; Brennan B; Brichard B; Brown KLB; Butterfass-Bahloul T; Calaminus G; Daldrup-Link HE; Eriksson M; Gebhardt MC; Gelderblom H; Gerss J; Goldsby R; Goorin A; Gorlick R; Grier HE; Hale JP; Hall KS; Hardes J; Hawkins DS; Helmke K; Hogendoorn PCW; Isakoff MS; Janeway KA; Jürgens H; Kager L; Kühne T; Lau CC; Leavey PJ; Lessnick SL; Mascarenhas L; Meyers PA; Mottl H; Nathrath M; Papai Z; Randall RL; Reichardt P; Renard M; Safwat AA; Schwartz CL; Stevens MCG; Strauss SJ; Teot L; Werner M; Sydes MR; Whelan JS Lancet Oncol; 2016 Oct; 17(10):1396-1408. PubMed ID: 27569442 [TBL] [Abstract][Full Text] [Related]
17. Undetectable phospho-STAT1 in peripheral blood mononuclear cells from patients with chronic hepatitis C who do not respond to interferon-alpha therapy. Aceti A; Zechini B; Griggi T; Marangi M; Pasquazzi C; Quaranta G; Sorice M Liver Int; 2005 Oct; 25(5):987-93. PubMed ID: 16162158 [TBL] [Abstract][Full Text] [Related]
18. EURAMOS-1, an international randomised study for osteosarcoma: results from pre-randomisation treatment. Whelan JS; Bielack SS; Marina N; Smeland S; Jovic G; Hook JM; Krailo M; Anninga J; Butterfass-Bahloul T; Böhling T; Calaminus G; Capra M; Deffenbaugh C; Dhooge C; Eriksson M; Flanagan AM; Gelderblom H; Goorin A; Gorlick R; Gosheger G; Grimer RJ; Hall KS; Helmke K; Hogendoorn PC; Jundt G; Kager L; Kuehne T; Lau CC; Letson GD; Meyer J; Meyers PA; Morris C; Mottl H; Nadel H; Nagarajan R; Randall RL; Schomberg P; Schwarz R; Teot LA; Sydes MR; Bernstein M; Ann Oncol; 2015 Feb; 26(2):407-14. PubMed ID: 25421877 [TBL] [Abstract][Full Text] [Related]
19. Phase I study of the sequential combination of interleukin-12 and interferon alfa-2b in advanced cancer: evidence for modulation of interferon signaling pathways by interleukin-12. Eisenbeis CF; Lesinski GB; Anghelina M; Parihar R; Valentino D; Liu J; Nadella P; Sundaram P; Young DC; Sznol M; Walker MJ; Carson WE J Clin Oncol; 2005 Dec; 23(34):8835-44. PubMed ID: 16314644 [TBL] [Abstract][Full Text] [Related]
20. Tim3/Gal9 interactions between T cells and monocytes result in an immunosuppressive feedback loop that inhibits Th1 responses in osteosarcoma patients. Li X; Chen Y; Liu X; Zhang J; He X; Teng G; Yu D Int Immunopharmacol; 2017 Mar; 44():153-159. PubMed ID: 28103502 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]